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Abstract: 
Cataract was used as a model for the prevalence and economic impact of adverse events during the drug 
development process. Meta-analysis revealed a reported prevalence of cataract of 12.0% (1.0-43.3%), 
3.8% (2.4-12.5%), 1.0% (0.0-8.1%), 1.7% (0.0-34.8%) and 3.8% (2.3-5.7%) of compounds in Pre-
clinical, Phase I, II, III and IV clinical trials, respectively.  Utilizing a human-based in vitro screening 
assay to predict cataractogenic potential in man could allow better selection of novel compounds at early 
stage drug development. This could significantly reduce costs and ultimately increase the probability of 
a drug obtaining FDA approval for a clinical application. 
 
Word count: 97 
3 
 
Background: 
Fully assessing the impact of contraindications during the traditional drug development process is 
notoriously difficult given that the vast majority of “negative studies” remain unpublished. Thus, 
existing drug development models, while producing compounds which afford clinically significant 
results for specific indications are also accompanied by adverse events whose treatment and 
management can be both extensive and expensive. If such adverse events are sufficiently severe, the 
drug will warrant withdrawal from the market. In the United States, for example, it has been estimated 
that only between 1 in 5,000 to 10,000 potential compounds receives final market approval by the Food 
and Drug Administration (FDA) [1]. Problems can also arise during pre-clinical animal trials, which can 
cessate further development of a given compound. Much of the traditional drug development process is, 
therefore, fraught with inefficiencies and wasted resources and requires greater refinement in candidate 
selection as well as greater prediction of targeted effects and the mitigation of harmful adverse events in 
human beings. Drug-induced cataract is one such significant adverse event for a number of systemic 
compounds. Moreover, cataract can arise during pre-clinical animal trials, which can result in 
withdrawal of that candidate from the drug development programme.  
 Overall, the drug development process is comprised of a number of stages including: pre-clinical 
(safety and dosing studies on animals) and human clinical trials consisting of Phase I or dose-ranging 
safety studies, Phase II efficacy and safety studies often against placebo, Phase III efficacy and safety 
studies with a therapeutic dose and Phase IV or post-marketing utilisation studies of the drug. Thus, the 
potential for drug failure in clinical trials is an important source of both costs and a range of adverse 
events, such as cataract [2]. Hay et al, for instance, concluded that the success rates of compounds 
undergoing Phase I trials which ultimately received final registration was only 10% [3]. Given such a 
high attrition rate for compounds, the high number of adverse events stopping trials from proceeding 
and the high costs of drug development, it is exceedingly useful to better understand the full magnitude 
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and costs associated with adverse events during the drug development process as well as the potential 
role of an early stage screening assay to improve drug candidate selection. To achieve this we assessed 
cataract as a model outcome as it is a recognised adverse event that can be observed and recorded non-
invasively. Cataract also has a specific treatment which has a defined cost associated with its treatment 
(surgical removal of cataract). More precisely, our aims were twofold: i) to undertake a systematic 
literature review of the scientific literature on the reported prevalence of cataract as an example of an 
adverse event amongst compounds undergoing drug development, and ii) using such evidence as 
gleaned from this systematic review and other sources to develop a simplified economic model to 
estimate the cost implications arising from possible cataractogenic adverse events during the drug 
development process as well as to explore the impact of a possible screening assay to reduce the 
probability of incurring such adverse events.    
Methods: 
i) Systematic literature search:   
The primary research question addressed by the systematic literature search was how prevalent is 
cataract as an adverse event in the drug development process? The main literature database searched 
was Google Scholar over the period January 1990 to May 2015 for pre-clinical animal studies and over 
the period January 2005 to May 2015 for clinical studies in humans. It has elsewhere been shown that 
Google Scholar provides a high degree of coverage and precision with regards to similar literature 
search engines, such as PubMed/MED [4]. To find clinical trials, the search strategy involved using 
terms such as "phase I trial" cataract where trial was replaced with study and clinical and the phase was 
varied. Papers mentioning clinical trials in the titles of articles were examined, and the word cataract 
was searched to determine whether cataracts formed as adverse events, or were only mentioned in the 
introduction, for example. For post-acceptance trials, the search terms double-blind adverse cataract 
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was used, and for animal studies the phrase preclinical animal adverse cataract was used. To ensure 
high levels of evidence from the literature review, the inclusion criteria used to determine the 
cataractogenic properties of possible compounds were only derived from well conducted randomised 
clinical trials or case-control studies. Similarly, case series and case report studies were excluded from 
the analysis.  
ii) Economic model: 
The economic model was developed in Visual Basic Applications (VBA) Microsoft ® Office Excel 
(Microsoft Corporation). The input parameters for each phase were imported from a spreadsheet into the 
VBA macro. These include parameters used to assess the trial itself: the number of patients, the 
probability of a favourable outcome in each phase of the trial, the reported probability of developing 
cataract as an adverse event in both the treatment and control groups, the nominal cost per patient for 
each phase of the trial, the cost of treating cataracts, the time spent in each phase of the trial, the branded 
drug price, the number of prescriptions written, which was set equal to one million and the discount rate.   
The model routinely evaluated each patient in the drug development phase, and at each stage there was a 
defined probability of favourable outcome and progressing to the next phase of the trial. For each patient 
a uniform random number between zero and one was sampled, and if this random number was less than 
the probability of a favourable outcome, the number of favourable outcomes was incremented. The same 
procedure was done for cataracts for each patient. It was possible, for example, for a single patient to 
develop cataracts but still be cured, thus the probabilities are independent. This evaluation was repeated 
for each patient in both the treatment and control groups.  The trial phase was considered to have passed 
if: A) the difference between the number of favourable outcomes in the treatment in the control groups 
was greater than twice the square root of the number of patients (corresponding roughly to p=0·025) and 
B) the difference between the number of adverse events, was not greater than twice the square root of 
the number, according to the same metric. The economic model assumes that the drug being developed 
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was for a life-threatening disease, such as, cancer. In such a circumstance, the presence of cataract, as an 
adverse event, significantly impact a patient’s vision and overall quality of life and therefore patients in 
the model undergo cataract surgery to remedy this. The use of a screening assay which reduces the 
healthcare costs associated with treating adverse events and the savings to be redeployed towards 
providing life-saving drugs for an even greater number of patients from the same total fixed healthcare 
budget are also modelled. Each phase was iterated one thousand times, and the fraction of iterations that 
passed was taken as the probability of the trial passing. If a trial passed, the excess number of adverse 
events, that is, cataracts in the treatment group is compared to the control group and is recorded and 
averaged over all passed trials out of the thousand. The costs were calculated by multiplying this 
average excess by the cost for cataracts surgery, based on a discount rate compounded annually and 
applied at the end of the phase. The total cost was calculated as the sum of the nominal costs and the 
cost of the excess cataracts, and this was divided by the number of sales at a given price in order to 
calculate the break-even time required to offset the overall cost of the drug trial. 
The key direct healthcare costs included in the model are comprised of: i) the cost of the conducting the 
pre-clinical and human clinical trials of the drug or compound under investigation during each phase of 
the drug development process (Pre-clinical, Phase I through III, as no trial based costs accrue in Phase 
IV) [5-6]; and ii) the costs associated with cataract surgery costs for which published reference tariffs 
from the National Health System (NHS) in the United Kingdom were used [7]. Indirect costs, such as 
reduced productivity amongst trial participants were excluded from our model, as they are difficult to 
fully capture. Such indirect costs are, however, likely to be substantial and thus our simplified economic 
model must be viewed as an underestimate of the full costs associated with developing a new drug. The 
time horizon of the analysis was that of the entire drug development life-cycle and this was also taken 
from the literature [8]. The economic model used a discount rate of 3·5% per annum to handle the time 
preference of money for alternative uses of drug development funds [9]. Lastly, as little data on the 
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mean value of branded drug prices was available, the mean price of branded drug prices was derived 
from a review of the average price of branded drug in Canada (found to be CDN $ 80·88 or US$ 65·40), 
yielding a working branded price of range between US$ 30 to US$ 90 for our simplified economic 
model [10].  All cost data were converted from local currencies into US dollars. 
Results: 
i) Systematic literature search 
As noted above, Google scholar was the primary tool used for literature research. It searched through 
scholarly literature, including those publications indexed by other services such as PubMed, using the 
full text rather than specifically focusing on the title or authors. Papers whose full text could not be 
accessed from the McGill University Library were excluded unless cataract information was found in 
the abstract. For each search phrase (eleven in total, three for each stage and one each for pre- and post-
clinical), the first sixty results were examined in depth. Towards the sixtieth result, articles were rarely 
relevant, and no relevant articles were found in the sixty-first through eightieth results, thus only the first 
sixty were focused on. This led to a total of six hundred and sixty articles that were initially considered 
for review. Out of these, a total of forty-one papers were examined in detail as they definitively reported 
on cases of cataracts in the paper.  
 Our results are stratified according to the various phase of the drug development process. The main 
findings from the systematic literature search are presented in Tables 1. As can be seen in Table 1, 
12.0% (Range: 1.0-43.3%) of animals in the pre-clinical stage developed cataract. Table 1 also  presents 
the impact of small scale Phase I, or safety studies of compounds in humans with  an average reported  
prevalence of cataract of 3.8% (Range: 2.4-12.5%). Many of the systemic compounds reported as 
causing cataract occurred in conditions such as cancer which were life-threatening. Table 1 similarly 
highlights the prevalence of cataract among Phase II studies with a figure of 1.0% (Range: 0.0-8.1%). 
Equally, Table 1 presents the prevalence of cataract among compounds undergoing Phase III clinical 
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development, finding that the average value was 1.7% (Range: 0.0-34.8%) of compounds.  Finally, the 
later part of Table 1 presents the findings for post-marketing surveillance or Phase IV data on published 
reports and found that the prevalence of cataract as an adverse event was  3.8% (Range: 2.3-5.7%).  
ii) Economic model 
The model was implemented using data from the literature search conducted above. The basic 
assumptions and inputs used in the economic model are presented in Table 2. The probability of 
developing cataract in each phase of the trial was given by the difference in the probability between the 
control and treatment groups. In the case of the base case scenario, this was set to the range given by the 
reported prevalence values obtained in the literature search conducted above. It is estimated that the total 
cost of completing pre-clinical and clinical trials for a single compound is US$ 32,380,000. Drawing on 
data collected from the economic model, the financial benefits of a good predictive screening tool for 
adverse events, such as cataract can be considered on two levels. The first concerns the savings arising 
from identifying a side-effect in a drug designed to treat a non-life threatening condition. In such cases 
the drug would normally be withdrawn at some stage from the drug development process. If a drug was 
hypothetically withdrawn following pre-clinical animal trials, early detection by a screening assay, 
would save US$ 4,448,162, following phase I clinical trials US$ 5,447,989, at the end of phase II 
clinical trials US$ 7,095,541, at the end of phase III clinical trials US$ 31,349,265 and after Phase IV 
some US$ 32,378,610 respectively. An additional scenario relates to drugs that will be used to treat a 
life threatening disorder; in such cases, a number of adverse events, including cataract, are deemed to be 
acceptable. Nevertheless, development of an effective drug that does not display an adverse event is still 
preferable. If a pre-clinical screening assay can lead to an improved drug selection i.e. an efficacious 
drug independent of a severe adverse event then this could, in the case of potential cataract screening, 
reduce the overall cost of a trial and reduce the break-even time for a single compound. Table 3 presents 
these findings and displays the impact which a screening assay might have upon the overall branded 
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drug price and the break-even time to recover the financial investment made by the manufacturer to 
develop a new drug. As can be seen given the assumptions of the model, approximately US$ 1,057,349 
might be theoretically saved as a result of using some sort of screening assay to discriminate amongst 
compounds entering the drug development process. Moreover, using a mean branded drug price of US$ 
65.40, this translates in to roughly 16,167 extra prescriptions which might be written and potential lives 
saved, with less adverse events in the process.  
Discussion: 
i) Systematic review 
Despite focusing solely upon cataracts, our review and model is illustrative of the significant impact 
which adverse events pose to the drug development process and the scope for future improvements. In 
2013 alone, for example, it was been estimated that as many as 4.12 million scientific procedures were 
started on animals in Great Britain alone [11]. Moreover, it has been well documented that animal 
models translate rather poorly to human models of disease and are such of limited overall utility [12-13].  
In this respect, FDA has noted that “... nine out of ten experimental drugs fail in clinical studies because 
we cannot accurately predict how they will behave in people based on laboratory and animal studies” 
[14]. Thus, the low probability of being successful in the early pre-clinical animal modelling phase, 
potentially translates into significant downstream economic costs for drugs which are more likely to be 
accompanied by multiple adverse events.  Lastly, it is likely that if it was possible to include data from 
unpublished “negative studies” the true prevalence of cataract and indeed of other adverse events in the 
drug development process would be even higher than have been modelled.  
ii) Economic model 
Economically, the avoidance of adverse events, such as cataract, in the drug development process is of 
great importance to individual pharmaceutical manufacturer’s being able to maximise the return on their 
scarce research and development budgets. While it was not possible to obtain direct economic data on 
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the cost of adverse events due to the clinical drug development process from an industry wide 
perspective, our model has attempted to predict the economic impact of improvements made as a result 
of the use of a hypothetical assay or biomarker to screen out compounds likely to produce a single 
adverse event, namely cataract. Ceteris paribus, the use of a screening assay would pay for itself 
relatively quickly, as drug manufactures would be better able to triage which compounds were more 
likely to yield promising so-called “on target” effects versus more deleterious “off target” effects and so 
halt development on less promising compounds earlier on in the drug development process, thereby 
resulting in direct cost savings which could then be ploughed back into finding ever more refined 
compounds for clinical development. 
iii) The case of cataract considered 
Unlike other organ or tissues systems in the human body, the lens presents an isolated tissue system 
which might enable effective screening biomarkers or assays to be developed. The diversity of 
physiological response between species is demonstrated by in vitro whole lens culture which shows 
distinct patterns of response to receptor associated ligands in the rat and differs to those observed in 
human lenses cultured under the same conditions [15].  Moreover, the sensitivity of the lens to various 
drugs across the species will differ and thus whole lens in vitro cultures can be used as one level of 
predictive testing for adverse side effects for the respective species in vivo. Equally, in terms of high 
throughput screening, human lens cell lines could provide a relatively cheap and efficient system and 
could serve as a possible predictor for the outcome of human clinical trials. Importantly such screening 
assays could flag early problems and so avoid needless animal usage and potentially adverse events in 
human clinical trials at least in so far as systemic compounds causing cataractogenic adverse events are 
concerned [16]. However, additional consideration should be made regarding the limited blood supply 
to the lens and the likelihood of specific agents entering the eye and accruing in the ocular humours that 
bathe the lens [2]. 
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Moreover, such a possible screening assay may well serve to improve the efficaciousness of those drugs 
which are brought to market and increase the so-called “on-target effects” and so minimise the “off-
target effects”. In addition, by avoiding the potential for adverse events, like cataract formation, 
pharmaceutical manufacturers will be avoiding the downstream costs of treating such adverse conditions 
should these develop in the context of their human clinical drug trial. This paradigm shift could 
represent a move towards what might be termed “Informed drug discovery or development” with 
manufacturers more fully aware that certain compounds are more likely to cause a range of unintended 
and potentially costly healthcare interventions.  Overall, our systematic literature search is necessarily 
limited given the much larger number of unknowable “negative studies” regarding cataract formation in 
the drug development process and more should be done to capture these significant missing pieces of the 
overall puzzle. As such, the development of a cost-effective pre-clinical screening procedure involving 
human cell/tissue models located in the lens may hold considerable promise in terms of reducing drug 
induced cataract during the drug development process. This approach could with modification to this 
and other therapeutic areas provide both economic benefits to companies and importantly improve the 
wellbeing of millions of patients by producing safer, more efficacious, and more targeted medications 
with fewer adverse events.  
iv) Final thoughts  
While our research has focussed on cataractogenic adverse events attributable to systemic compounds 
and medications, the general principles presented here using cataract as a case study are applicable to 
other tissues associated with specific adverse events, such as liver toxicity, which impact on animals and 
humans alike in the drug development process. As demonstrated in our simplified economic model, a 
relatively modest decrease in the probability of developing cataract within the drug development process 
reduces not only the costs of conducting the trials, but also the break-even time to recoup outlays 
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expended on research and development. As researchers in other disease areas have shown there is a need 
to better understand the translational interplay between rodent and human biomarkers or assays 
particularly for detecting specific tissue changes relative to baseline levels and potentially targeted 
therapeutic effects [17-19]. Such tissue-focussed systems would provide a clear signal to encourage drug 
manufacturers to adopt a much more proactive stance to combat the enormous scale of the problem due 
to too many drugs with many more “off-target” than “on-target” effects and the accompanying plethora 
of adverse events, as well as the ever spiralling drug development and healthcare costs due to treating 
these adverse events.  
In the final analysis while drug manufacturers will probably need to be convinced or incentivised to 
make such dramatic changes in how they bring new drugs to market, novel screening assays already in 
hand or close to being developed could prove pivotal to bringing new more efficacious pharmaceuticals 
to market. In an era of both constrained industry research and public healthcare budgets those companies 
which adopt such screening assays technologies will not only be likely to secure new patents, but are 
also likely to secure favourable pricing and reimbursement status as well. Let us, therefore, go back to 
our labs and offices and go forth determined to improve the tools and techniques by which new drugs 
are discovered, tested, developed, approved and used.  
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Legends for Tables 
Table 1: Findings from a systematic review detailing the prevalence of cataract according to 
specific drug development phase  
 
Table 2: Key economic model inputs and assumptions on the overall impact of drug development 
under both base case and screening assay conditions  
 
Table 3: Key economic model outputs according to branded drug price, break-even time and 
overall cost of the trial  
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Table 1:  
Study Aim Compound of 
interest 
Animal 
used/Phase 
Number  of 
animals used 
Number of 
cataract eyes 
Prevalence of  
Cataract %  (Range) 
Impacted Drug 
Progression 
Reference 
Pre-clinical        
Carcigenocity Tamoxifen Rats 103 38 36·8 No [20] 
Carcigenocity Toremifene Rats 400 4 1·0 No [21] 
Cataract 
induction 
Doxorubicin Rats 60 26 43.3 No [22] 
Overall Pre-
clinical 
  563 -68 12.0% (1.0-43.3%)   
Phase I        
Retinoblastoma 
With Vitreous 
Tumor Seeding 
Mediated 
Delivery of 
Thymidine 
Kinase Followed 
by Ganciclovir 
I 8 1 12.5 No [23] 
Retinoblastoma Intra-Arterial 
Chemotherapy 
I 78 2 2.5 No [24] 
Cancer Tipifarnib and 
Capecitabine 
I 41 1 2.4 No [25] 
Solid tumors and 
lymphomas 
PF-04929113 I 33 1 3.0 Yes [26] 
Lung Cancer Gefitinib with 
radiation and 
cisplatin 
I 14 1 7.1 Yes [27] 
Retinal 
Degeneration 
Ciliary 
neurotrophic 
factor 
I 10 1 10.0 No [28] 
Myeloma NVP-AUY922 I 24 1 4.2 No [29] 
Overall     208 
 8  3.8 % (2.4-12.5%)   
Phase II        
Macular edema Ranibizumab II 10 0 0.0 No [30] 
Gynaecologic 
cancers 
Ixapebilone II 49 1 2.0 No [31] 
Retinoblastoma Intra-arterial 
chemotherapy 
II 78 0 0.0 No [32] 
Macular edema Dexamethasone II 997 0 0.0 No [33] 
Lymphomas Radiation II 37 3 8.1 No [34] 
Alzheimer’s Bapineuzumab II 125 5 4.0 Yes [35] 
Breast cancer Gemcitabine II 68 1 1.5 No [36] 
Lung cancer Cetuximab and 
chemoradiation 
II 34 1 2.9 No [37] 
Macular Edema Dexamethasone II 315 7 2·2 No [38] 
Overall Phase II    1713 
 18 1.0% (0.0-8.1%)   
Phase III        
Dry Eye Cyclosporine III 412 3 0.7 No [39] 
Macular 
Degeneration 
Ranibizumab III 4,300 3 0.0 No [40] 
Macular 
Degeneration 
Ranibizumab & 
Verteporfin 
III 423 11 2.6 No [41] 
Macular Edema Ranibizumab III 261 14 5.4 No [42] 
Macular Edema Ranibuzimab III 264 5 1.9 No [43] 
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Chronic 
obstructive 
pulmonary 
disease 
Mometasone 
furate/formeterol 
fumarate 
III 1,196 6 0.5 Followed up [44] 
Macular Edema Triamcinolone 
acetonide 
III 43 15 34.8 Followed up [45] 
Macular 
Degeneration 
Ranibizumab III 249 1 0.4 No [46] 
Macular Edema Ranibizumab III 377 3 0.8 No [47] 
Prostate Cancer Denosumab III 734 35 4.8 No [48] 
Myeloma Thalidomide & 
Prednisone 
III 332 6 1.8 No [49] 
Glaucoma Tafluprost & 
Latanoprost 
III 402 18 4.5 No [50] 
Macular 
Degeneration 
Pegaptanib 
sodium 
III 161 23 14.3 No [51] 
Diabetes Ezetimibe III 152 1 0.7 No [52] 
Myeloma Lenalidomide 
and low-dose 
dexamethasone 
arm 
III 1076 38 3.5 No [53] 
Alzheimer’s Placebo III 1054 12 1·1 No [54] 
Overall Phase III    11,436 
 194 1.7% (0.0-34.8%)   
Phase IV        
Breast cancer Armiidex and 
Tamoxifen 
IV 9,366 395 4.2 No [55] 
Arthritis Glucocorticoids IV 27 1 3.7 No [56] 
Breast cancer Tamoxifen, 
Raloxifene, & 
Aromatas 
IV 19,471 707 3.6 No [57] 
Arthritis Prednisolone IV 192 11 5.7 No [58] 
Post-Kidney 
transplant 
Corticosteroids IV 386 9 2.3 No [59] 
Arthritis Methotrexate IV 70 2 2.9 No [60] 
Overall Phase IV    29,512  1,125 3.8% (2.3-5.7%)   
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Table 2:  
 
Variable of Interest Pr
e-
Cl
in
ic
al
 
Ph
as
e 
I 
Ph
as
e 
II
 
Ph
as
e 
III
 
Ph
as
e 
IV
 
R
ef
er
en
ce
 
Model Inputs       
Number of Animals/Patients 800 80 100 1,000 10,000 9 
Discount rate = 3.5%      10 
Average branded price US$ 65.40      11 
Expected yearly sales = 1,000,000 units      Model 
Time for phase of the trial in years 3 1.8 2.1 2.5 2 9 
Cost of cataracts surgery for both eyes 
(US$) 0 2,710 2,710 2,710 2,710 8 
Initial nominal cost per animal/patient in 
trial (US$)  
7,500 15,700 19,300 26,000 0 6,7  
 
      
Control Parameters  
      
Probability of a favourable outcome (a) 0.4 0.15 0.32 0.26 0.1 Model 
Probability of adverse event (i.e. cataract) 
(b) 
0.1 0.05 0.02 0.02 0.01 Model 
       
Treatment Parameters  (Base case, no 
screening assay)  
      
Probability of a favourable outcome (c) 0.8 0.9 0.8 0.9 1.0 Model 
Probability of adverse event (i.e. cataract) 
(d) 
0.22 0.088 0.03 0.037 0.048 Model 
       
Conditional probability of success in 
each stage of the trial (CP=c-a) 
0.40 0.75 0.48 0.64 0.90 9 
       
Conditional probability of cataract in 
each stage of the trial (CP=d-b) 
0.12 0.038 0.01 0.017 0.038 Systematic 
review 
       
Treatment Parameters  (Screening Assay)       
Probability of a favourable outcome 0.8 0.9 0.8 0.9 1.0 Model 
Probability of adverse event (i.e. cataract) 0.1 0.05 0.02 0.02 0.01 (Base equal 
to controls ) 
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Table 3:  
Base case scenario Branded Price (US$) Break-even time (Years) Cost of trial (US$)  
 30 1.08 32,378,611.66 
 40 0.81 32,380,458.38 
 50 0.65 32,380,064.45 
 60 0.54 32,380,182.75 
 70 0.46 32,380,427.01 
 80 0.40 32,379,367.41 
 90 0.36 32,380,891.32 
Mean cost   32,380,000.43 
 
   
Screening Assay 30 1.04 31,322,474.13  
 40 0.78 31,322,964.69  
 50 0.63 31,322,248.77  
 60 0.52 31,322,645.77  
 70 0.45 31,322,366.26  
 80 0.39 31,322,744.66  
 90 0.35 31,323,115.81  
Mean cost    31,322,651.44  
    
Difference in cost   1,057,348.99  
N.B. Costs are calculate from the economic model and therefore vary slightly from one price point to the next 
 
 
 
